Objective To analyze the clinical efficacy and adverse reactions of desloratadine citrate decre-mental therapy in treatment of chronic urticaria.Methods 162 cases of patients with chronic urticaria were selected, they were randomly divided into observation group and control group.Control group was given routine treatment of desloratadine citrate capsule,while the observation group was given desloratadine citrate capsule decreasing therapy, the therapeutic effect and the levels of serum immunoglobulins were compared between the two groups.Results After treatment,the total effective rate of the observation group was 95.06%,there was no significant difference compared with 92.59% of the control group (χ2 =3.254,P >0.05);Two weeks and four weeks after treatment,IgE levels were significantly lower than before treatment,there were significant difference (t =8.291,7.931,6.936,5.152,all P <0.05),and the observation group change was more significant,the differences between the two groups were statistically significant (t =7.913,8.136,all P <0.05).After treatment symptom score was significantly lower than before treat-ment,and there were significant difference (t =7.519,8.015,all P <0.05),but the differences between groups were not significant (t =3.152,2.781,all P >0.05).The recurrence rate in the treatment group was 19.75%,which was significantly lower than the 40.74% of the control group,the difference between the two groups was statistically signif-icant (χ2 =6.914,P <0.05).But there was no significant difference in the incidence of adverse reactions between the two groups (χ2 =1.927,P >0.05).Conclusion Desloratadine citrate capsules in treatment of chronic urticaria can not only obtain more effective clinical curative effect,but also has less toxic side effect.For the purposes of the application method of the drug,decreasing method compared with conventional medication therapy can effectively improve the level of serum IgE.Therefore,it is worthy of clinical application.

Objective To explore the effect and toxicity of S -1 combined with oxaliplatin neoadjuvant chemotherapy in treatment of advanced gastric cancer.Methods 70 patients with gastric cancer were divided into the study group and the control group by using the random number table method,35 cases in each group.The study group was given neoadjuvant chemotherapy with S -1 combined with oxaliplatin,and the control group was treated with FOLFOX regimen.After three cycles of treatment,the effect and the toxicity of the two groups were observed and com-pared.Results The total effective rate of the study group was 71.43%,which was significantly higher than 45.71%(16 /35)of the control group (χ2 =5.02,P <0.05).The CD8 and CD4 /CD8 in the study group before and after radiotherapy had statistically significant difference (P <0.05 ).WBC and neutrophils in the control group had significant difference before and after treatment (P <0.05),CD8,CD4 /CD8 in the study group were significantly higher than those in control group (P <0.05).The incidence of gastrointestinal adverse reactions in the control group was significantly higher than that in the study group (χ2 =3.75.4.02,all P <0.05).The 1 year survival rate in the study group was 85.71%,2 years survival rate was 57.14%,the recurrence rates of 1 year and 2 years were 20.00%,40.00%,which in the control group were 71.43%,42.86%,22.86%,42.86%,the differences were not statistically significant (χ2 =1.02,0.79,0.90,1.05,all P >0.05).Conclusion S -1 combined with oxaliplatin neoadjuvant chemotherapy has good effect in treatment of advanced gastric cancer,the side reaction is small,with high safety.